// STATE LEGISLATION TRACKER

Washington HB 2419: Studying barriers to the use of the Washington death with dignity act.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Vetoed

State: Washington
Bill: HB 2419
Filed: 2020-01-14
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Washington HB 2419 would have required the University of Washington to study barriers to using the state's Death with Dignity Act. It does not appear to regulate peptides, compounded medications, off-label prescribing, telehealth, clinician scope, controlled substances, or prescription monitoring.

Key Points

No direct impact on compounded peptide access
No change to off-label prescribing rules
No change to NP or naturopathic scope for peptides
No apparent 503A or 503B compounding effect
No peptide-related telehealth or prescribing change

What to Watch For

Note The bill focused on end-of-life medication access, not peptide care or wellness prescribing.

Note Any future death-with-dignity changes could affect controlled medication workflows, but this bill did not.

Note For peptide users and clinicians, this is informational only and needs no practice change.

Where the Bill Stands

The bill passed both chambers in March 2020 but was vetoed by the governor on April 3, 2020.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws